We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+0.31%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.95B
AUM Growth
-$162M
Cap. Flow
+$94.6M
Cap. Flow %
3.21%
Top 10 Hldgs %
48.26%
Holding
91
New
14
Increased
7
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.4M
2
CGEM icon
Cullinan Oncology
CGEM
+$43.6M
3
NUVB icon
Nuvation Bio
NUVB
+$39.6M
4
CNTB
Connect Biopharma Holdings
CNTB
+$35.4M
5
IMVT icon
Immunovant
IMVT
+$26.4M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$116M
2
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.3M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$25.9M
4
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$19.4M
5
CLDX icon
Celldex Therapeutics
CLDX
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.52%
2 Financials 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PNT
51
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$15.8M 0.53%
1,500,000
– –
CDAK
52
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$15.5M 0.53%
1,030,065
+427,415
+71% +$9.29M
MIST icon
53
Milestone Pharmaceuticals
MIST
$138M
$14.9M 0.51%
2,572,194
+95,000
+4% +$695K
RNAC icon
54
Cartesian Therapeutics
RNAC
$229M
$14.9M 0.5%
109,469
– –
ESPR
55
DELISTED
Esperion Therapeutics
ESPR
$14M 0.48%
500,000
– –
MTNB icon
56
Matinas BioPharma
MTNB
$1.88M
$12.1M 0.41%
229,573
– –
PSTX
57
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$11.9M 0.41%
1,251,055
– –
BLU
58
DELISTED
BELLUS Health Inc.
BLU
$11.4M 0.39%
2,975,000
– –
AGEN
59
Agenus
AGEN
$312M
$10.9M 0.37%
203,800
– –
ARYD
60
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$10.3M 0.35%
+750,000
New +$8.1M
LITS
61
Lite Strategy Inc
LITS
$32.8M
$9.99M 0.34%
145,655
– –
CERE
62
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$9.81M 0.33%
714,500
-600,000
-46% -$8.78M
QURE icon
63
uniQure
QURE
$3.03B
$8.42M 0.29%
250,000
– –
VINCU
64
DELISTED
Vincerx Pharma, Inc. Unit
VINCU
$8.1M 0.27%
+300,000
New +$8.26M
ASMB icon
65
Assembly Biosciences
ASMB
$498M
$6.9M 0.23%
125,000
– –
MIRM icon
66
Mirum Pharmaceuticals
MIRM
$6.46B
$6.28M 0.21%
317,000
– –
IMMP
67
Immutep
IMMP
$56.3M
$6.14M 0.21%
+2,000,000
New +$6.09M
KNSA icon
68
Kiniksa Pharmaceuticals
KNSA
$5.8B
$5.38M 0.18%
290,577
– –
BLSA
69
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.29M 0.18%
500,000
– –
RACB
70
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$5.13M 0.17%
+500,000
New +$5.12M
JYAC
71
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.92M 0.17%
500,000
– –
ORIC icon
72
Oric Pharmaceuticals
ORIC
$1.15B
$4.9M 0.17%
200,000
– –
OBIO icon
73
Orchestra BioMed
OBIO
$238M
$4.48M 0.15%
400,000
– –
SYRE icon
74
Spyre Therapeutics
SYRE
$8.54B
$4.36M 0.15%
22,000
– –
MLTX icon
75
MoonLake Immunotherapeutics
MLTX
$1.57B
$4.08M 0.14%
400,000
– –
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Boxer Capital held 91 positions worth $2.95B, down 5.2% from $3.11B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Boxer Capital deployed $94.6M of net new capital in Q1 2021, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Cullinan Oncology: 1,074,082 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $116M trimmed.

  • Boxer Capital's largest Q1 2021 buy was Cullinan Oncology: 1,074,082 shares worth $44.8M.
  • Boxer Capital added most to Mirati Therapeutics, Inc. Common Stock in Q1 2021, an estimated $46.4M increase.
  • Boxer Capital's biggest Q1 2021 reduction was BeOne Medicines Ltd, cutting an estimated $116M.
  • Boxer Capital fully exited Pandion Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $31.3M.
  • Boxer Capital's ten largest holdings make up 48% of its $2.95B portfolio in Q1 2021.
  • Boxer Capital opened 14 new positions and closed 6 in Q1 2021.
  • Boxer Capital's portfolio value fell 5.2% quarter-over-quarter to $2.95B.

Based on Boxer Capital's 13F filing for Q1 2021, filed 17 May 2021.